ArticleJournal of asthma and allergy2021
Effectiveness and Response Predictors of Omalizumab in Treating Patients with Seasonal Allergic Rhinitis: A Real-World Study.
Article in Journal of asthma and allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Comparison of the efficacy of different doses of omalizumab (150 mg vs 300 mg) in patients with seasonal allergic rhinitis and low total IgE: A randomized, double-blind, controlled study.The World Allergy Organization journal · 2026Article
- Update on pediatric allergic rhinitis: narrative review based on guideline updates.Clinical and experimental pediatrics · 2026Review
- Review
- Toward personalized prediction: a multicenter machine learning model for omalizumab response duration in moderate-to-severe perennial allergic rhinitis.Frontiers in allergy · 2026Article
- The Immunogenetic Landscape of Allergic Rhinitis: from Cellular Effectors to Gene Regulation and Targeted Therapies.International journal of biological sciences · 2026Review
- Efficacy of Biologics on Nasal Symptoms in Severe Asthmatics: We Need Additional Biomarkers or Strategies to Assess Phenotypes or Endotypes.Allergy, asthma & immunology research · 2025Article
- LP-003, a novel high-affinity anti-IgE antibody for inadequately controlled seasonal allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled phase 2 clinical trial.Clinical and translational allergy · 2025Article
- Recent Studies and Prospects of Biologics in Allergic Rhinitis Treatment.International journal of molecular sciences · 2025Review
- A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database.Scientific reports · 2025Article
- Efficacy of Biologic Therapies in the Management of Allergic Rhinitis: A Systematic Review.Cureus · 2024Review
- Pediatric usage of Omalizumab: A promising one.The World Allergy Organization journal · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOmalizumab has been proven effective and safety in treating seasonal allergic rhinitis (SAR) by several randomized clinical trials in many countries. However, there is lack of clinical reports of Chinese patients with SAR treated by omalizumab.
objectiveIn the present real-world-designed study, we aimed to investigate the effectiveness of omalizumab in treating patients with SAR.
methodsSAR patients administered omalizumab in various dosages were recruited, and follow-up was done. Their quality of life (QOL) and symptoms were assessed by the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), Total Nasal Symptoms Score (TNSS), Asthma Control Test (ACT), and clinical outcomes were compared between post- and pre-treatment conditions.
resultsSixty SAR patients received omalizumab therapy in the study (mean age 35.47±17.02 years, 35 females). Omalizumab treatment significantly improved the quality of life (change in RQLQ overall score: -2.08±1.01, paired
conclusionOmalizumab is effective and safe in SAR treatment in a real-world setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.